Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe the pharmaceutical industry was effective at tackling the pandemic, boosting its reputation last year to the highest level in a decade. But at the same time, a majority of the groups also found that, besides research and development, drug makers were lacking in most other areas of operation.
Specifically, 62% of the groups believed the industry, as a whole, dealt effectively with the coronavirus. For this reason, half of the groups feel that drug companies now have an excellent or good reputation, according to the survey by PatientView, a research firm that canvassed 1,920 groups from 84 countries between November 2020 and February 2021. They rated the reputations of 48 drug makers.